Literature DB >> 33035330

Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.

Damien Luque Paz1,2,3,4, Rébecca Jouanneau-Courville3,4, Jérémie Riou5, Jean-Christophe Ianotto4,6, Françoise Boyer4,7, Aurélie Chauveau4,8,9, Maxime Renard1,2,3,4, Jean-Claude Chomel4,10, Emilie Cayssials4,11, Maria-Pilar Gallego-Hernanz4,11, Cédric Pastoret4,12, Anne Murati13, Frédéric Courtier13, Marie-Christine Rousselet14, Isabelle Quintin-Roué15, Laurane Cottin1,2,3,4, Corentin Orvain4,7, Sylvain Thépot1,4,7, Jean-Marie Chrétien16, Yves Delneste1, Norbert Ifrah1,2,4,7, Odile Blanchet1,2,3,4,17, Mathilde Hunault-Berger1,2,4,7, Eric Lippert4,8,9, Valérie Ugo1,2,3,4.   

Abstract

Among myeloproliferative neoplasms, polycythemia vera (PV) and essential thrombocythemia (ET) are the 2 entities associated with the most chronic disease course. Leukemic evolution occurs rarely but has a grim prognosis. The interval between diagnosis and leukemic evolution is highly variable, from a few years to >20 years. We performed a molecular evaluation of 49 leukemic transformations of PV and ET by targeted next-generation sequencing. Using a hierarchical classification, we identified 3 molecular groups associated with a distinct time to leukemic transformation. Short-term transformations were mostly characterized by a complex molecular landscape and mutations in IDH1/2, RUNX1, and U2AF1 genes, whereas long-term transformations were associated with mutations in TP53, NRAS, and BCORL1 genes. Studying paired samples from chronic phase and transformation, we detected some mutations already present during the chronic phase, either with a significant allele burden (short-term transformation) or with a very low allele burden (especially TP53 mutations). However, other mutations were not detected even 1 year before leukemic transformation. Our results suggest that the leukemic transformation of PV and ET may be driven by distinct time-dependent molecular mechanisms.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 33035330      PMCID: PMC7556129          DOI: 10.1182/bloodadvances.2020002271

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  45 in total

1.  Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.

Authors:  Alicia Senín; Concepción Fernández-Rodríguez; Beatriz Bellosillo; Laura Camacho; Raquel Longarón; Anna Angona; Carles Besses; Alberto Álvarez-Larrán
Journal:  Ann Hematol       Date:  2017-11-27       Impact factor: 3.673

2.  Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.

Authors:  Rishu Agarwal; Piers Blombery; Michelle McBean; Kate Jones; Andrew Fellowes; Ken Doig; Cecily Forsyth; David A Westerman
Journal:  Ann Hematol       Date:  2017-02-04       Impact factor: 3.673

Review 3.  Genomics of Myeloproliferative Neoplasms.

Authors:  Katerina Zoi; Nicholas C P Cross
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

4.  Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia.

Authors:  Alberto Alvarez-Larrán; Alicia Senín; Concepción Fernández-Rodríguez; Arturo Pereira; Eduardo Arellano-Rodrigo; Montse Gómez; Francisca Ferrer-Marin; Joaquín Martínez-López; Laura Camacho; Dolors Colomer; Anna Angona; Blanca Navarro; Francisco Cervantes; Carlos Besses; Beatriz Bellosillo; Juan Carlos Hernández-Boluda
Journal:  Br J Haematol       Date:  2017-05-23       Impact factor: 6.998

5.  Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.

Authors:  Guido Finazzi; Vanesa Caruso; Roberto Marchioli; Giovanni Capnist; Teodoro Chisesi; Carlo Finelli; Luigi Gugliotta; Raffaele Landolfi; Jack Kutti; Heinz Gisslinger; Raphael Marilus; Carlo Patrono; Enrico Maria Pogliani; Maria Luigia Randi; Ana Villegas; Gianni Tognoni; Tiziano Barbui
Journal:  Blood       Date:  2004-12-07       Impact factor: 22.113

6.  The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.

Authors:  Constantine S Tam; Roberto M Nussenzveig; Uday Popat; Carlos E Bueso-Ramos; Deborah A Thomas; Jorge A Cortes; Richard E Champlin; Stefan E Ciurea; Taghi Manshouri; Sherry M Pierce; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2008-06-19       Impact factor: 22.113

7.  JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.

Authors:  Isabelle Plo; Mayuka Nakatake; Laurent Malivert; Jean-Pierre de Villartay; Stéphane Giraudier; Jean-Luc Villeval; Lisa Wiesmuller; William Vainchenker
Journal:  Blood       Date:  2008-05-30       Impact factor: 22.113

8.  Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.

Authors:  Mandy Brecqueville; Jérôme Rey; François Bertucci; Emilie Coppin; Pascal Finetti; Nadine Carbuccia; Nathalie Cervera; Véronique Gelsi-Boyer; Christine Arnoulet; Olivier Gisserot; Denis Verrot; Borhane Slama; Norbert Vey; Marie-Joelle Mozziconacci; Daniel Birnbaum; Anne Murati
Journal:  Genes Chromosomes Cancer       Date:  2012-04-09       Impact factor: 4.263

9.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

10.  Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.

Authors:  B Kubesova; S Pavlova; J Malcikova; J Kabathova; L Radova; N Tom; B Tichy; K Plevova; B Kantorova; K Fiedorova; M Slavikova; V Bystry; J Kissova; B Gisslinger; H Gisslinger; M Penka; J Mayer; R Kralovics; S Pospisilova; M Doubek
Journal:  Leukemia       Date:  2017-07-24       Impact factor: 11.528

View more
  13 in total

1.  An Polycythemia Vera Evolve from Acute Myeloid Leukemia? Report of a Case Showing a Simultaneous Minor JAK2 V617F Mutated Clone.

Authors:  Beatrice Borsellino; Arianna Savi; Maria Rosaria Pascale; Elisa Meddi; Maria Ilaria Del Principe; Antonio Cristiano; Tiziana Ottone; Maria Cristina Rapanotti; Mariadomenica Divona; Serena Travaglini; Enrico Attardi; Raffaele Palmieri; Elisa Buzzatti; Francesco Buccisano; Maria Teresa Voso
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-07-01       Impact factor: 3.122

Review 2.  The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).

Authors:  F Nguyen-Khac; A Bidet; A Daudignon; M Lafage-Pochitaloff; G Ameye; C Bilhou-Nabéra; E Chapiro; M A Collonge-Rame; W Cuccuini; N Douet-Guilbert; V Eclache; I Luquet; L Michaux; N Nadal; D Penther; B Quilichini; C Terre; C Lefebvre; M-B Troadec; L Véronèse
Journal:  Leukemia       Date:  2022-04-16       Impact factor: 12.883

Review 3.  Genetic Background of Polycythemia Vera.

Authors:  Mathilde Regimbeau; Romain Mary; François Hermetet; François Girodon
Journal:  Genes (Basel)       Date:  2022-04-02       Impact factor: 4.141

Review 4.  BCOR gene alterations in hematologic diseases.

Authors:  Paolo Sportoletti; Daniele Sorcini; Brunangelo Falini
Journal:  Blood       Date:  2021-12-16       Impact factor: 22.113

Review 5.  Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies.

Authors:  Vincenzo Nasillo; Giovanni Riva; Ambra Paolini; Fabio Forghieri; Luca Roncati; Beatrice Lusenti; Monica Maccaferri; Andrea Messerotti; Valeria Pioli; Andrea Gilioli; Francesca Bettelli; Davide Giusti; Patrizia Barozzi; Ivana Lagreca; Rossana Maffei; Roberto Marasca; Leonardo Potenza; Patrizia Comoli; Rossella Manfredini; Antonino Maiorana; Enrico Tagliafico; Mario Luppi; Tommaso Trenti
Journal:  Int J Mol Sci       Date:  2021-02-14       Impact factor: 5.923

Review 6.  Acute Myeloid Leukemia Evolving from Myeloproliferative Neoplasms: Many Sides of a Challenging Disease.

Authors:  Francesco Mannelli
Journal:  J Clin Med       Date:  2021-01-23       Impact factor: 4.241

Review 7.  JAK2 Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms.

Authors:  Dania G Torres; Jhemerson Paes; Allyson G da Costa; Adriana Malheiro; George V Silva; Lucivana P de Souza Mourão; Andréa M Tarragô
Journal:  Biomolecules       Date:  2022-02-11

Review 8.  Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.

Authors:  Ruth Stuckey; María Teresa Gómez-Casares
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

Review 9.  Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence.

Authors:  Galia Stemer; Jacob M Rowe; Yishai Ofran
Journal:  Blood Lymphat Cancer       Date:  2021-06-22

10.  Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.

Authors:  Jean Pegliasco; Pierre Hirsch; Christophe Marzac; Françoise Isnard; Jean-Côme Meniane; Caroline Deswarte; Philippe Pellet; Céline Lemaitre; Gwendoline Leroy; Graciela Rabadan Moraes; Hélène Guermouche; Barbara Schmaltz-Panneau; Florence Pasquier; Chrystelle Colas; Patrick R Benusiglio; Odile Bera; Jean-Henri Bourhis; Eolia Brissot; Olivier Caron; Samy Chraibi; Pascale Cony-Makhoul; Christine Delaunay-Darivon; Simona Lapusan; Flore Sicre de Fontbrune; Pascal Fuseau; Albert Najman; William Vainchenker; François Delhommeau; Jean-Baptiste Micol; Isabelle Plo; Christine Bellanné-Chantelot
Journal:  Leukemia       Date:  2021-06-25       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.